Dr. Jack Seki is a research faculty member specializing in hematology/oncology and clinical pharmacology, with a discovery-driven focus on optimizing drug safety and therapeutic continuity in high-risk cancer populations. This foundational work has deepened understanding of thrombosis risk in pediatric-inspired asparaginase-based ALL treatment (Native, PEG-, recombinant), highlighting the role of primary prophylaxis and its application in mitigating coagulopathy across inpatient and ambulatory settings. It continues to inform refinement of risk stratification models through real-world data and mechanistic insights.
Building on prior supportive care work, Dr. Jack Seki is leading a clinical trial, investigating desensitization protocols for multiple myeloma patients with hypersensitivity to immunomodulatory agents (IMiDs). The research aims to preserve access to essential therapies while minimizing adverse events, supporting safe and uninterrupted treatment. As IMiDs remain central to evolving combination regimens, successful desensitization is critical to maintaining therapeutic continuity and optimizing survival outcome. Dr. Jack Seki is conducting a systematic review of published studies on integrating blinatumomab into frontline MRD (+/–) ALL therapy. Using translational modeling and biomarker-driven analysis, the work compares survival and treatment-related mortality against standard chemotherapy, aiming to contextualize blinatumomab’s impact within existing cytotoxic frameworks and real-world clinical design.
Publications
Keywords: Asparaginase-associated thrombosis, Venous thromboembolism (VTE), Acute lymphoblastic leukemia, Coagulopathy, Antithrombin deficiency, Central venous catheter (CVC) complications, PICC line thrombosis, Thrombosis prophylaxis, Low molecular weight heparin (LMWH), Direct oral anticoagulants (DOACs) Clinical Practice & Guidelines, ISTH thrombosis guidelines, Pediatric vs adult ALL protocols, Induction phase complications, Supportive care in leukemia Re: IMiDs agents and HSR Core Terms, Immunomodulatory drugs (IMiDs), Lenalidomide hypersensitivity, Pomalidomide reactions, Drug desensitization protocols, Hypersensitivity reactions, Cutaneous adverse drug reactions (CADRs), Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN) Therapeutic Context, Multiple myeloma combination therapy, Doublet, triplet, quadruplet regimens, Treatment continuity, Supportive care in hematologic malignancies, Multidisciplinary management